Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2023-503230-49-00 | Other Identifier | EU CT |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will evaluate the pharmacokinetics (PK), safety, tolerability, pharmacodynamics (PD), and efficacy of ELX/TEZ/IVA in CF subjects 12 to less than (<) 24 months of age.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Part A | Experimental | Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening. |
|
| Part B | Experimental | Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening with the dose(s) to be based on the outcome of Part A. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ELX/TEZ/IVA | Drug | Fixed-dose combination granules for oral administration. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Part A: Observed Pre-dose Concentration (Ctrough) of ELX, TEZ, IVA, and their Relevant Metabolites | Day 1 up to Day 15 | |
| Part A: Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Day 1 up to Day 43 | |
| Part B: Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Day 1 up to Week 28 |
| Measure | Description | Time Frame |
|---|---|---|
| Part B: Observed Pre-dose Concentration (Ctrough) of ELX, TEZ, IVA, and their Relevant Metabolites | Day 15 up to Week 16 | |
| Part B: Absolute Change in Sweat Chloride (SwCl) | From Baseline Through Week 24 |
Not provided
Key Inclusion Criteria:
Participants who have at least 1 F508del mutation in the CF transmembrane conductance regulator (CFTR) gene or another ELX/TEZ/IVA-responsive CFTR mutation
Key Exclusion Criteria:
History of any illness or any clinical condition that, in the opinion of the investigator, might either confound the results of the study or pose an additional risk in administering study drug(s) to the participant
Other protocol defined Inclusion/Exclusion criteria may apply.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Telethon Kids Institute | Nedlands | Australia | ||||
| The Royal Children's Hospital |
Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| IVA | Drug | Granules for oral administration |
|
|
| Parkville |
| Australia |
| Queensland Children's Hospital | South Brisbane | Australia |
| The Children's Hospital at Westmead | Westmead | Australia |
| The Hospital for Sick Children | Toronto | Canada |
| British Columbia Children's Hospital | Vancouver | Canada |
| Juliane Marie Center, Rigshospitalet | Copenhagen | Denmark |
| Charite Paediatric Pulmonology Department | Berlin | Germany |
| Kinderklinik III, Abt. fur Pneumologie | Essen | Germany |
| Medizinische Hochschule Hannover | Hanover | Germany |
| Erasmus Medical Center / Sophia Children's Hospital | Rotterdam | Netherlands |
| Inselspital - Universitaetsspital Bern | Bern | Switzerland |
| Kinderspital Zuerich | Zurich | Switzerland |
| Children and Young Adults Research Unit | Cardiff | United Kingdom |
| Leeds General Infirmary | Leeds | United Kingdom |
| Alder Hey Children's NHS Foundation Trust | Liverpool | United Kingdom |
| Great Ormond Street Hospital for Children | London | United Kingdom |
| Royal Brompton Hospital | London | United Kingdom |
| Southampton General Hospital | Southampton | United Kingdom |
| ID | Term |
|---|---|
| D003550 | Cystic Fibrosis |
| ID | Term |
|---|---|
| D010182 | Pancreatic Diseases |
| D004066 | Digestive System Diseases |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D007232 | Infant, Newborn, Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000706587 | elexacaftor, ivacaftor, tezacaftor drug combination |
| C545203 | ivacaftor |
Not provided
Not provided
Not provided